Carmelo Bengala

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study

Richard S. Finn, Carmelo Bengala, Nuhad K. Ibrahim et al. · Clinical Cancer Research · 2011 · 216 citations

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

Carmelo Bengala, Federica Bertolini, N. Malavasi et al. · British Journal of Cancer · 2009 · 215 citations · Full text

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Denise A. Yardley, Rob Coleman, Pierfranco Conté et al. · Annals of Oncology · 2018 · 130 citations · Full text

Cardiotoxicity of Epirubicin/Paclitaxel–Containing Regimens: Role of Cardiac Risk Factors

Alessandra Gennari, B. Salvadori, Sara Donati et al. · Journal of Clinical Oncology · 1999 · 114 citations